Clinical trial
Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis
NCT00163280 · Alizyme, Industry · Completed
Key facts
| NCT number | NCT00163280 |
|---|---|
| Title | Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis |
| Official title | Randomised Double-Blind Placebo-Controlled Study of Orally Administered ATL-104 to Assess Safety, Tolerance and Effect on Oral Mucositis in Patients Following Treatment With Chemotherapy and Peripheral Blood Stem Cell Transplant (PBSCT) |
| Lead sponsor | Alizyme, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mucositis |
| Intervention type | Drug |
| Interventions | ATL-104 |
| Enrollment | 63 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Feb 12, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: